The pharmaceutical giant Amgen has finalized an agreement to purchase Dark Blue Therapeutics, a UK-based biotechnology firm. The total valuation... Read more
Category: Uncategorized
Pfizer and Cartography Biosciences collaborate to discover tumor-selective antigens
Global pharmaceutical leader Pfizer has entered into a multi-year strategic collaboration with Cartography Biosciences to identify novel tumor-selective antigens. The... Read more
Eli Lilly taps Nimbus in $1.3bn deal for second obesity candidate
For the second time, Eli Lilly has joined forces with Boston-based Nimbus Therapeutics to advance a potential weight-loss therapy. The... Read more
Health Canada authorizes first siRNA therapy for rare Lipid Disorder
On January 6, 2026, Health Canada granted authorization to Arrowhead Pharmaceuticals for Redemplo (plozasiran). This milestone marks the first small... Read more
AstraZeneca and BostonGene partner to accelerate oncology R&D via multimodal AI
On January 6, 2026, BostonGene, a developer of foundational AI models for tumor and immune biology, announced a strategic collaboration... Read more
First oral GLP-1 weight-loss pill enters U.S. market
On January 5, 2026, Novo Nordisk officially launched the oral version of Wegovy (semaglutide) in the United States. This marks... Read more
AbbVie and Zejing forge strategic alliance for DLL3-targeted cancer therapy
On January 5, 2026, AbbVie entered into a licensing option agreement with China-based Zejing Biopharmaceutical to advance the global development... Read more
Singapore firm raises $50m to advance AI-driven clinical trial automation
Deep Intelligent Pharma (DIP), a Singapore-based leader in medical AI, has secured $50 million in Series D funding. The new... Read more
Skye Bioscience licenses Halozyme’s delivery technology to enhance obesity treatment
On January 5, 2026, Skye Bioscience Inc. and Halozyme Therapeutics Inc. announced a global non-exclusive collaboration and licensing agreement to... Read more









